Project 1: Roles and Regulation of Mutant p53 and ANp63 in Breast Cancer Cells Carol Prives, Ph.D. Increasing evidence supports the likelihood that, in stark contrast to wild-type p53, tumor-derived mutant forms of p53 play roles in fostering tumor development, invasion and metastasis. To gain insight into the mechanism by which mutant p53 may play a role in breast cancer we adopted the "3D" protocol in which placing normal mammary epithelial cells (such as MCF10A cells) into an extracellular matrix-rich environment leads to their assembling into acinar structures with hollow lumens that resemble the terminal ducts of the mammary gland. We discovered that expression of mutant p53 in MCF10A cells leads to acini with filled rather than hollow lumens, while shRNA mediated down-regulation of mutant p53 in 2 breast cancer cell lines leads to reduced invasive behavior in one case (MDA-231 cells) and conversion of disordered structures into proper hollow acini in the other case (MDA-468 cells). To understand how mutant p53 prevents mammary cells from forming proper acini we will pursue the observation that mutant p53 up-regulates integrin ?4 in 3D culture conditions and integrin ?4 regulates invasive behavior in MD-231 cells. In collaboration with Scott Lowe and Arnold Levine we will pursue another discovery that mutant p53 increases levels of several enzymes involved in sterol biosynthesis when cell are plated in 3D culture conditions, and that treatment of such cells with statins leads to reduced invasive behavior and cell death. In each case we will seek the mechanism by which mutant p53 regulates these pathways. Another potential regulator of cell proliferation is the ?Np63a isoform of p63. We previously discovered that levels of ?Np63a are maintained by a novel protein (Stxbp4) and reduced by another protein (Rack 1) whose ability to induce degradation of ?Np63a is repressed by Stxbp4. We have now identified the APC/C E3 ubiquitin ligase complex as another regulator of ?Np63a turnover and have shown that it's degradation of ?Np63a is blocked by Stxbp4. Since our data and that of our co-program member Carlos Cordon-Cardo indicate that ?Np63 likely plays pro-proliferative and tumorigenic roles (including prevention of acinar luminal clearing in 3D cultures) we will elucidate the role of Stxbp4 in stabilizing ?Np63 and seek ways to prevent their interaction. Finally we will investigate the roles of p63 and p73 in regulation of formation of acinar like structures in the 3D culture setting and will determine whether the abilities of ?Np63a and mutant p53 to prevent luminal hollowing work by similar or different mechanisms.

Public Health Relevance

Both mutant forms of p53 and the AN forms of p63 have been implicated in breast and bladder cancer; two of the major forms of human cancer. The goal of this program is to determine the mechanisms by which mutant p53 and DeltaNp63 regulate novel pathways discovered under the auspices of this program that are involved in these and other forms of cancer. The experiments we propose in many cases are derived from and dependent on inter-program collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA087497-14
Application #
8706066
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
14
Fiscal Year
2014
Total Cost
$437,376
Indirect Cost
$82,598
Name
Columbia University (N.Y.)
Department
Type
DUNS #
049179401
City
New York
State
NY
Country
United States
Zip Code
10027
Miething, Cornelius; Scuoppo, Claudio; Bosbach, Benedikt et al. (2014) PTEN action in leukaemia dictated by the tissue microenvironment. Nature 510:402-6
Jia, A Y; Castillo-Martin, M; Bonal, D M et al. (2014) MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. Br J Cancer 110:2945-54
Barber, Alison G; Castillo-Martin, Mireia; Bonal, Dennis M et al. (2014) Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PLoS One 9:e98786
Chen, Chong; Liu, Yu; Rappaport, Amy R et al. (2014) MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25:652-65
Jia, Angela Y; Castillo-Martin, Mireia; Domingo-Domenech, Josep et al. (2013) A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. Am J Pathol 182:1171-9
Mills, John R; Malina, Abba; Lee, Teresa et al. (2013) RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an E?-myc/Bcl-2 mouse model. Blood 121:3402-12
Freed-Pastor, William A; Mizuno, Hideaki; Zhao, Xi et al. (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148:244-58
Shen, Tian Huai; Gladoun, Nataliya; Castillo-Martin, Mireia et al. (2012) A BAC-based transgenic mouse specifically expresses an inducible Cre in the urothelium. PLoS One 7:e35243
Karni-Schmidt, Orit; Castillo-Martin, Mireia; Shen, Tian Huai et al. (2011) Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 178:1350-60
Wosnitzer, Matthew S; Domingo-Domenech, Josep; Castillo-Martin, Mireia et al. (2011) Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol 186:2094-100

Showing the most recent 10 out of 68 publications